Individual DSMB recommends Inhibitex to outmanoeuvre FV-100 Work in II clinical headache in requital for shingles
Inhibitex, Inc. (Nasdaq: INHX) today announced that the disinterested information cover monitoring accommodate (DSMB) important in requital for reviewing cover materials from the Company’s persistent Taper off II clinical misery of FV-100 met, as scheduled, after the Body had provided it with get up on become 30-day follow-up security materials on the third quartile (75%) of the patients that the Theatre troupe plans to enroll in the conditional. Based upon its rehashing, the DSMB recommended that the attempt persevere in to end without modification. The Plc anticipates that top-line efficacy text from the completed judicial proceeding bequeath be handy in the fourth region of 2010.
The Time II pilot is a well-controlled, double-blind retreat comparing two arms of FV-100 to an effective button (valacyclovir) in the treatment of shingles, also referred to as herpes zoster. The Callers plans to enroll and equally randomize almost 350 patients, ancient 50 years and older, to anecdote of three treatment arms: 200 mg FV-100 administered for good occasionally regular; 400 mg FV-100 administered instantly ordinary; and 1,000 mg valacyclovir administered three times per daylight. In totting up to naval evaluating its safe keeping, the objectives of the experimental are to gauge the the right stuff health-giving sake of FV-100 in reducing the flintiness and duration of shingles-associated grieve, the extent of stanchion herpetic neuralgia (PHN), and the tempo to lesion healing.
FOUNTAIN-HEAD Inhibitex, Inc.,
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
